Novartis Starts Trial for ASA404 in Lung Cancer
April 16th, 2008
Novartis’ nonsmall cell lung cancer drug ASA404, which is designed to selectively reduce blood supply to tumors, has entered a Phase III trial.
The randomized, double-blind, placebo-controlled, multicenter ATTRACT-1 study will evaluate ASA404 in combination with paclitaxel and carboplatin as a first-line treatment for locally advanced or metastatic nonsmall cell lung cancer.